Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-651-5p antagomir
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Research Use Only, Typically Intravenous Or Intratumoral Injection In Animal Models
01
Overview
**miR-651-5p antagomir** is a chemically engineered antisense oligonucleotide designed to specifically inhibit the activity of microRNA miR-651-5p. This antagomir binds to miR-651-5p and prevents it from interacting with its target mRNAs, reversing its gene-silencing effects. In preclinical studies with EGFR-mutant non-small cell lung cancer (NSCLC), miR-651-5p antagomir increased infiltration of CD8+ T cells, decreased immune cell apoptosis, and enhanced the efficacy of PD-1 inhibitor immunotherapy. Mechanistically, miR-651-5p promotes apoptosis by downregulating BCL2 expression in T cells, and the antagomir restores BCL2, supporting anti-tumor immune response. No information is available on commercial developers or manufacturers, and it is currently an investigational research reagent used in academic studies[1][8].
- Other names
- miR-651-5p inhibitormiR651-5p inhibitormiR 651-5p inhibitormiR-651-5p antagonistmiR651-5p antagonistmiR 651-5p antagonist
Beyond the preview
Go deeper on miR-651-5p antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-651-5p antagomir.